Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2011, Article ID 960137, 4 pages
http://dx.doi.org/10.1155/2011/960137
Review Article

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas

Institute of Hematology, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy

Received 15 July 2010; Accepted 18 February 2011

Academic Editor: A. Ganser

Copyright © 2011 Claudio Fozza and Maurizio Longinotti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Mellors, “Autoimmune disease in NZB-Bl mice. II. Autoimmunity and malignant lymphoma,” Blood, vol. 27, no. 4, pp. 435–448, 1966. View at Google Scholar · View at Scopus
  2. E. Ekström Smedby, C. M. Vajdic, M. Falster et al., “Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium,” Blood, vol. 111, no. 8, pp. 4029–4038, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. L. A. Anderson, S. Gadalla, L. M. Morton et al., “Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies,” International Journal of Cancer, vol. 125, no. 2, pp. 398–405, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. C. C. Goodnow, “Multistep pathogenesis of autoimmune disease,” Cell, vol. 130, no. 1, pp. 25–35, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. T. J. Hamblin, “Autoimmune complications of chronic lymphocytic leukemia,” Seminars in Oncology, vol. 33, no. 2, pp. 230–239, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. Sallah, G. Sigounas, P. Vos, J. Y. Wan, and N. P. Nguyen, “Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance,” Annals of Oncology, vol. 11, no. 12, pp. 1571–1577, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Economopoulos, N. Stathakis, M. Constantinidou, E. Papageorgiou, C. Anastassiou, and S. Raptis, “Cold agglutinin disease in non-Hodgkin's lymphoma,” European Journal of Haematology, vol. 55, no. 1, pp. 69–71, 1995. View at Google Scholar · View at Scopus
  8. H. E. Eve and S. A. J. Rule, “Autoimmune haemolytic anaemia associated with mantle cell lymphoma,” International Journal of Hematology, vol. 91, no. 2, pp. 322–325, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. Osterborg, C. Karlsson, and J. Lundin, “Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia,” Current Hematologic Malignancy Reports, vol. 4, no. 1, pp. 47–53, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. M. J. Overman, L. Feng, B. Pro et al., “The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma,” Annals of Oncology, vol. 19, no. 3, pp. 553–559, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. K. Fu, D. D. Weisenburger, W. W. L. Choi et al., “Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4587–4594, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Zecca, P. De Stefano, B. Nobili, and F. Locatelli, “Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia,” Blood, vol. 97, no. 12, pp. 3995–3997, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Quartier, B. Brethon, P. Philippet, J. Landman-Parker, F. Le Deist, and A. Fischer, “Treatment of childhood autoimmune haemolytic anaemia with rituximab,” The Lancet, vol. 358, no. 9292, pp. 1511–1513, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. T. D. Shanafelt, H. L. Madueme, R. C. Wolf, and A. Tefferi, “Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome,” Mayo Clinic Proceedings, vol. 78, no. 11, pp. 1340–1346, 2003. View at Google Scholar · View at Scopus
  15. G. D'Arena, C. Califano, M. Annunziata et al., “Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients,” European Journal of Haematology, vol. 79, no. 1, pp. 53–58, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. Dierickx, G. Verhoef, A. van Hoof et al., “Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study,” Journal of Internal Medicine, vol. 266, no. 5, pp. 484–491, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. G. Bussone, E. Ribeiro, A. Dechartres et al., “Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases,” American Journal of Hematology, vol. 84, no. 3, pp. 153–157, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. L. Borche, A. Lim, J. L. Binet, and G. Dighiero, “Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies,” Blood, vol. 76, no. 3, pp. 562–569, 1990. View at Google Scholar · View at Scopus
  19. G. Dighiero and L. Borche, “Evidence that the B lymphocyte proliferating in B-CLL and in other B-CELL malignancies is frequently commited to production of natural autoantibodies,” Nouvelle Revue Francaise d'Hematologie, vol. 32, no. 5, pp. 323–326, 1990. View at Google Scholar · View at Scopus
  20. E. J. Lee and B. Kueck, “Rituxan in the treatment of cold agglutinin disease,” Blood, vol. 92, no. 9, pp. 3490–3491, 1998. View at Google Scholar
  21. F. Bauduer, “Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD2O-positive, low-grade non-Hodgkin's lymphoma,” British Journal of Haematology, vol. 112, no. 4, pp. 1085–1086, 2001. View at Publisher · View at Google Scholar
  22. Y. Cohen, A. Polliack, O. Zelig, and A. Goldfarb, “Monotherapy with Rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lympho-plasmcytic lymphoma,” Leukemia and Lymphoma, vol. 42, no. 6, pp. 1405–1408, 2001. View at Google Scholar
  23. N. Layios, E. van den Neste, E. Jost, V. Deneys, J. M. Scheiff, and A. Ferrant, “Remission of severe cold agglutinin disease after rituximab therapy,” Leukemia, vol. 15, no. 1, pp. 187–188, 2001. View at Publisher · View at Google Scholar
  24. A. Mori, J. I. Tamaru, H. Sumi, and H. Kondo, “Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy,” European Journal of Haematology, vol. 68, no. 4, pp. 243–246, 2002. View at Publisher · View at Google Scholar
  25. S. Paydas, S. Yavuz, U. Disel, B. Sahin, and M. Ergin, “Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase,” Leukemia and Lymphoma, vol. 44, no. 12, pp. 2165–2166, 2003. View at Publisher · View at Google Scholar
  26. J. Petit, M. Clavo, A. F. de Sevilla, E. González-Barca, E. Domingo-Doménech, and A. Grañena, “Refractory cold agglutinin-immunohaemolytic anaemia associated to marginal zone lymphoma responding to rituximab,” Hematology Journal, vol. 4, no. 6, pp. 450–451, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. A. Fabbri, A. Gozzetti, S. Lazzi et al., “Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia,” Clinical Lymphoma and Myeloma, vol. 6, no. 6, pp. 496–499, 2006. View at Publisher · View at Google Scholar
  28. N. Win, D. Tiwari, V. L. Keevil, M. Needs, and A. Lakhani, “Mixed-type autoimmune haemolytic anaemia: unusual cases and a case associated with splenic T cell angioimmunoblastic non-Hodgkins lymphoma,” Hematology, vol. 12, no. 2, pp. 159–162, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. C. Fozza, A. Galleu, M. G. Careddu et al., “Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma,” Annals of Hematology, vol. 89, no. 1, pp. 113–114, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. G. Seipelt, A. Böhme, S. Koschmieder, and D. Hoelzer, “Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome,” Annals of Hematology, vol. 80, no. 3, pp. 170–173, 2001. View at Publisher · View at Google Scholar
  31. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Berentsen, E. Ulvestad, R. Langholm et al., “Primary chronic cold agglutinin disease: a population based clinical study of 86 patients,” Haematologica, vol. 91, no. 4, pp. 460–466, 2006. View at Google Scholar
  33. S. Berentsen, E. Ulvestad, B. T. Gjertsen et al., “Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients,” Blood, vol. 103, no. 8, pp. 2925–2928, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. C. Schöllkopf, L. Kjeldsen, O. W. Bjerrum et al., “Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients,” Leukemia and Lymphoma, vol. 47, no. 2, pp. 253–260, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. E. Sigler, L. Shvidel, V. Yahalom, A. Berrebi, and M. Shtalrid, “Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion—severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab,” Transfusion, vol. 49, no. 7, pp. 1370–1374, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. E. M. Ocio, F. M. Sanchez-Guijo, M. Diez-Campelo et al., “Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena,” American Journal of Hematology, vol. 78, no. 4, pp. 302–305, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus